Longer-acting human growth hormone (hGH-CTP) receives orphan drug designation in Europe

Source: BioSpace Area: News The European Medicines has granted orphan drug designation to hGH-CTP, a longer-acting version of human growth hormone in development for the treatment of growth hormone deficiency. In Phase II studies in growth hormone-deficient adults, hGH-CTP was reported to be safe and well tolerated, and it demonstrated the potential to be administered once-weekly, replacing seven daily injections of currently marketed human growth hormone. The company PROLOR has initiated a phase II trial in children with growth hormone deficiency and plans a phase III trial in growth hormone-deficient adults, which is scheduled to begin later in 2013.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news